Level Four Advisory Services LLC Sells 35,230 Shares of CVS Health Co. (NYSE:CVS)

Level Four Advisory Services LLC lowered its stake in CVS Health Co. (NYSE:CVS - Free Report) by 26.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 97,294 shares of the pharmacy operator's stock after selling 35,230 shares during the quarter. Level Four Advisory Services LLC's holdings in CVS Health were worth $4,368,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Widmann Financial Services Inc. raised its position in CVS Health by 1.8% during the 3rd quarter. Widmann Financial Services Inc. now owns 11,506 shares of the pharmacy operator's stock valued at $724,000 after purchasing an additional 200 shares during the last quarter. EagleClaw Capital Managment LLC raised its holdings in shares of CVS Health by 3.4% during the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock valued at $275,000 after acquiring an additional 200 shares in the last quarter. Manchester Capital Management LLC lifted its stake in CVS Health by 4.8% in the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock worth $200,000 after acquiring an additional 204 shares during the period. Angeles Investment Advisors LLC boosted its stake in shares of CVS Health by 3.7% during the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock valued at $256,000 after purchasing an additional 204 shares in the last quarter. Finally, Rogco LP increased its position in shares of CVS Health by 3.2% during the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator's stock valued at $303,000 after buying an additional 210 shares during the period. Institutional investors own 80.66% of the company's stock.

Remove Ads

CVS Health Stock Performance

CVS traded up $0.16 during midday trading on Wednesday, reaching $68.14. The company had a trading volume of 2,231,440 shares, compared to its average volume of 11,556,475. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $75.27. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company has a market cap of $85.91 billion, a P/E ratio of 18.62, a P/E/G ratio of 0.98 and a beta of 0.54. The business has a 50-day moving average of $62.72 and a two-hundred day moving average of $57.83.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, equities research analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.90%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is currently 72.68%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. StockNews.com raised CVS Health from a "sell" rating to a "hold" rating in a research report on Thursday, February 13th. Leerink Partners raised CVS Health from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $55.00 to $75.00 in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a "hold" rating to a "buy" rating and set a $66.00 target price on the stock in a research report on Tuesday, December 3rd. Argus set a $77.00 target price on shares of CVS Health in a research note on Tuesday, February 18th. Finally, Barclays boosted their price target on CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, CVS Health has an average rating of "Moderate Buy" and an average price target of $70.39.

Insider Activity

In other CVS Health news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael F. Mahoney bought 30,000 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.24% of the company's stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.